An observational study in Ehlers-Danlos Syndrome, Hypermobile, Chronic Pain and Fatigue Syndrome, Chronic, sponsored by Centre Medical ISM (Integrative Systemic Medicine). Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Centre Medical ISM (Integrative Systemic Medicine) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Ehlers-Danlos Syndrome with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Ehlers-Danlos Syndrome · France.
Among the 13 studies in Ehlers-Danlos Syndrome with a site in France, this one is the only one that started in 2026, is one of 6 observational ones, and was the 13th registered.
67 studies on the registry are indexed under Ehlers-Danlos Syndrome; 24 are open to participants now.
Browse Ehlers-Danlos Syndrome studies →3 of the 13 studies in Ehlers-Danlos Syndrome with a site in France are open now. Recruiting first, the newest first:
University Hospital, Rouen · Sites in France
Ages 18–50 · Women only · Healthy volunteers
GCS Ramsay Santé pour l'Enseignement et la Recherche · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 12 Ehlers-Danlos Syndrome studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 25 is below the median of 150 across 33 observational studies indexed under Ehlers-Danlos Syndrome.
Median enrollment 48 across the 7 interventional studies, 116 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Centre Medical ISM (Integrative Systemic Medicine) as lead sponsor.
Centre Medical ISM (Integrative Systemic Medicine) has 1 study filed under Ehlers-Danlos Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Ehlers-Danlos Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07637084Centre Medical ISM (Integrative Systemic Medicine)Photobiomodulation for Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome (PBM-SEDh-01) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Ehlers-Danlos Syndrome with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the effect of photobiomodulation (PBM) therapy using a MLS® class IV laser on chronic pain and fatigue in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). hEDS is a hereditary connective tissue disorder characterized by joint hypermobility, chronic pain, and debilitating fatigue, for which therapeutic options remain limited.
Participants will receive 10 PBM sessions over 5 weeks (2 sessions per week), using red and near-infrared light (808 nm continuous + 905 nm pulsed) applied to painful areas identified at baseline. Pain (Visual Analogue Scale), multidimensional fatigue (MFI-20), and quality of life (EQ-5D-5L) will be assessed at baseline (T0), end of treatment (week 5), and follow-up (week 10).
This is a pilot observational study - the first to document the effect of MLS® laser PBM in hEDS. No additional procedures beyond routine care are required.
Background: Hypermobile Ehlers-Danlos Syndrome (hEDS) is the most common form of EDS (80-90% of cases), diagnosed according to the 2017 International Consortium criteria. Chronic pain and fatigue are the two most disabling symptoms. No randomized controlled trial has evaluated the effect of MLS® class IV laser photobiomodulation in hEDS to date.
Intervention: Photobiomodulation using ASAlaser M-Hi device (MLS® technology: synchronized 808nm continuous + 905nm pulsed emissions, CE MDR class IV). Progressive fluence: 4 J/cm² (sessions 1-2), 6 J/cm² (sessions 3-6), 8 J/cm² (sessions 7-10). Maximum 3-4 zones per session. Treatment areas individualized based on pain mapping at baseline.
Design: Single-center prospective observational pilot study in private practice. No randomization, no control group, no modification of ongoing treatment.
Statistical analysis: Wilcoxon signed-rank tests (paired, non-parametric), descriptive statistics. Exploratory pilot - no formal power calculation. Target sample size: 20-25 patients.
Adult patients with confirmed hypermobile Ehlers-Danlos Syndrome (hEDS), diagnosed according to the 2017 International Consortium criteria, presenting with chronic pain (≥ 3 months, VAS ≥ 4/10) and/or fatigue, followed in private outpatient practice at Centre Médical ISM, Boulogne-Billancourt, France. Patients are recruited consecutively among those already receiving photobiomodulation therapy as part of their routine care. No healthy volunteers are included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Change in chronic pain intensity
Change in pain intensity measured by the Visual Analogue Scale (VAS, 0-10), representing average pain over the preceding week. A decrease of ≥ 1.5 points is considered clinically meaningful.
Time frame: Baseline (T0) to Week 5 (end of PBM treatment cycle)
Durability of pain relief
Change in pain intensity assessed by the Visual Analogue Scale (VAS, 0-10, where 0 = no pain and 10 = worst pain imaginable; lower scores indicate less pain), between end of treatment (Week 5) and follow-up (Week 10), to assess persistence of the analgesic effect after PBM cessation
Time frame: Week 5 to Week 10 (5 weeks post-treatment follow-up)
Change in multidimensional fatigue
Change in fatigue assessed by the Multidimensional Fatigue Inventory (MFI-20), comprising 20 items across 5 subscales: General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue. Total score ranges from 20 to 100.
Time frame: Baseline (T0), Week 5 (T5), and Week 10 (T10)
Change in health-related quality of life
Change in quality of life assessed by the EQ-5D-5L questionnaire (5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and the EQ Visual Analogue Scale (EQ-VAS, 0-100).
Time frame: Baseline (T0), Week 5 (T5), and Week 10 (T10)
Tolerability of PBM therapy
Frequency and nature of local adverse events (redness, discomfort, transient pain aggravation) recorded at each session by the investigator.
Time frame: Each session, from Week 1 to Week 5 (sessions 1 to 10)
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.